Zevra Therapeutics (ZVRA)
NASDAQ:ZVRA
Earnings Data
Report Date
May 19, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.08Last Year’s EPS
-0.06Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a strong commercial and financial performance for 2025 highlighted by meaningful MIPLYFFA revenue ($87.4M), a full-year net income turnaround ($83.2M), expanding international access via EAP and active EU regulatory engagement. Key operational strengths include growing prescription starts (52 in 2025), 68% U.S. covered lives and a robust cash position ($238.9M). Challenges noted include quarter-to-quarter lumpiness inherent in an ultra-rare indication, elevated SG&A from launch investments, slower-than-desired enrollment/event accrual for the Celiprolol Phase III study (52/150 enrolled; 1/28 events), and some uncertainty around gross-to-net dynamics and regulatory/patent outcomes. On balance, the positives around commercialization, profitability, cash runway, and regulatory progress outweigh the manageable operational and clinical development headwinds.Company Guidance
Strong Full-Year and Quarterly Revenue
2025 net revenue of $106.5M with fourth-quarter net revenue of $34.1M. MIPLYFFA accounted for $87.4M (82% of full-year revenue) and $26.4M (77% of Q4 revenue), demonstrating commercial traction for the lead product.
Profitability Turnaround
Full-year 2025 net income of $83.2M ($1.40 basic, $1.35 diluted) compared to a net loss of $105.5M in 2024 — a swing of $188.7M. Q4 2025 net income was $12.2M versus a Q4 2024 net loss of $35.7M.
Commercial Momentum and Patient Starts
52 prescription enrollment forms in 2025 (24 in Q4) and 161 total enrollments since launch. Management estimates they have captured roughly 40%–50% of currently diagnosed U.S. patients, supporting confidence in longer-term uptake.
Expanded Access and International Footprint
Global expanded access program (EAP) had 113 patients enrolled at year-end 2025. New distribution agreements initiated shipments beyond Europe in Q4 and produced $5.6M of net EAP reimbursements in Q4 ($13M for the full year).
Regulatory Progress in Europe
Marketing Authorization Application submitted to the EMA (July 2025); received a 120-day list of questions at year-end and is prepared to respond within the 90-day clock-stop period, advancing EU approval pathway.
Strong U.S. Market Access
Covered Lives at 68% in the U.S. after the first full year on market, with management reporting strong reimbursement rates for remaining patients via market access and patient services efforts.
Healthy Balance Sheet
As of December 31, 2025, cash, cash equivalents and investments totaled $238.9M with total debt of approximately $61.9M, providing runway to execute commercial expansion and clinical programs.
Operating Expense Discipline & R&D Reduction
Full-year operating expenses decreased $6.6M year-over-year to $90.4M. R&D expense fell to $12.7M for the year, a decrease of $29.4M (≈69.8%) versus the prior year, reflecting lower personnel-related and third-party costs.
Clinical and Real-World Evidence Supporting MIPLYFFA
Company highlighted clinical differentiation: rapid onset of improvement in 12 weeks, halting progression at 12 months, and durable efficacy/safety >5 years. Presentations and EAP analyses demonstrated sustained benefit and strong adherence in multiyear follow-up.
ZVRA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ZVRA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 09, 2026 | $9.12 | $11.06 | +21.27% |
Nov 05, 2025 | $10.07 | $9.09 | -9.73% |
Aug 12, 2025 | $11.76 | $9.43 | -19.81% |
May 13, 2025 | $7.87 | $8.14 | +3.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Zevra Therapeutics (ZVRA) report earnings?
Zevra Therapeutics (ZVRA) is schdueled to report earning on May 19, 2026, TBA (Confirmed).
What is Zevra Therapeutics (ZVRA) earnings time?
Zevra Therapeutics (ZVRA) earnings time is at May 19, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZVRA EPS forecast?
ZVRA EPS forecast for the fiscal quarter 2026 (Q1) is 0.08.